Cure8 research brief
If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of life.
Adults with ulcerative colitis, gastroenterologists and IBD clinicians, and researchers interested in drug repurposing, SGLT2 biology, and AMPK-mediated anti-inflammatory mechanisms.
The study randomised 60 adults 1:1 to empagliflozin 25 mg daily versus placebo alongside standard background therapy for 6 months and used clinical (Montreal grade), quality-of-life (SF-36), and biomarker endpoints.
Reported benefits included higher response and remission rates and improvements in stool frequency, hemoglobin, ESR, and patient-reported quality of life; adverse events were described as minimal and similar between groups.
This brief is grounded in the article abstract provided by the preprint record on Research Square and summarizes the authors' reported findings. It does not substitute for peer review, guideline changes, or clinical advice. Consult your gastroenterology team before considering changes to treatment.
This posting is a trial report available as posted-content (Research Square) with abstract-level structured content; it appears to be registered on ClinicalTrials.gov. As a pilot-sized randomized study (n=60) and a preprint-style posting, results should be interpreted cautiously until peer-reviewed publication and independent replication.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Long-term real-world data on filgotinib help patients and clinicians understand how durable benefits and risks are over 2 years, including likelihood of staying on therapy and changes in inflammation markers.
People with IBD often have sleep problems and ongoing inflammation; melatonin could help both sleep and clinical disease activity, which may improve quality of life. The review suggests potential benefit but is not...
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
